Locations:
Search IconSearch

Tag: siRNA

edge of an apolipoprotein particle

Small-Interfering RNA Shows Cumulative Lp(a) Reduction With Successive Doses

Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA

23-HVI-4317309_lipoprotein(a)_650x450

Novel siRNA Reduces Lipoprotein(a) by More Than 90% for 48 Weeks

Undetectable levels achieved for nearly nine months in phase 1 trial

22-HVI-2769711_lipoprotein(a)_650x450

Novel siRNA Therapy Lowers Elevated Plasma Lipoprotein(a) in Phase 1 APOLLO Trial

Targeted mRNA blocking could be first effective approach specific to this cardiovascular risk factor

BackPage 1 of 1Next

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ad